News & Events about Cue Biopharma Inc.
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patients body, announced today that its President ...
Matteo Levisetti, M.D., promoted to Chief Medical Officer, effective January 17, 2023Acting CMO Kenneth Pienta, M.D., to transition to a clinical advisory role BOSTON, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel ...
Globe Newswire
2 months ago
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patients body, announced today that it will take part ...
Globe Newswire
2 months ago
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patients body, announced today that it has entered ...
Globe Newswire
3 months ago
Overall response rate (ORR) of 40% and a clinical benefit rate (CBR) of 70% observed to date in first line (1L) recurrent/metastatic HNSCC patients treated with CUE-101 at the recommended Phase 2 dose and pembrolizumab.Median overall survival (mOS) approaching greater than 12 months in third line ...